Chemical and Pharmaceutical Bulletin p. 782 - 786 (1998)
Update date:2022-07-30
Topics:
Martin-Martinez, Mercedes
Ballaz, Santiago
Latorre, Miriam
Herranz, Rosario
Garcia-Lopez, M. Teresa
Cenarruzabeitia, Edurne
Del Rio, Joaquin
Gonzalez-Muniz, Rosario
In order to find new classes of non-peptide cholecystokinin (CCK) ligands, the conformational restriction of a series of weak 3- oxoindolizidine-based CCK antagonists has been both decreased and increased. This tactic yielded a series of monocyclic 2-oxopyrrolidine derivatives 4 with selectivity for CCK-A or CCK-B receptors and with slightly improved binding affinity at the CCK-A receptor subtype with respect to the model 3- oxoindolizidines. In contrast, the incorporation of the Trp residue at the secondary amino group of a pyrrolo[1,2-a]pyrazine template 5, involving a drastic restriction in the conformational flexibility of the molecule, resulted in a series of bicyclic derivatives that did not bind to CCK receptors at concentrations up to 10-5 M.
View MoreXiamen Goodhealth Pharmchem Co., Ltd.
Contact:0086-592-2097683
Address:404R No.2 54# Minzu Rd., Xiamen, China
Jinan Xinke Pharmaceutical Science and Technology Co., Ltd.
Contact:+86 13256107535
Address:No. 592 the first gangxing road
Suzhou Health Chemicals Co., Ltd.
website:http://www.healthchems.com
Contact:13776257979
Address:No. 338, Jingang Avenue,
Jinan Decheng Hemu Medical Technology Co.,Ltd.
Contact:+86-531-68650525
Address:NO.554 Zhengfeng Road High-new Technology Development Zone
Refine Chemicals Science & Technology Technology Developing Co., Ltd.
Contact:+86-22-87899130
Address:No.12,west keyan road,Tianjin City
Doi:10.1080/00958972.2010.548862
(2011)Doi:10.1039/c0cc04677a
(2011)Doi:10.1021/jo980541v
(1998)Doi:10.1021/acschemneuro.6b00181
(2017)Doi:10.1016/j.jorganchem.2016.12.013
(2017)Doi:10.1021/jm000286i
(2000)